Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 10, 1440 doi:10.3324/haematol.11095
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, P. T.
Right arrow Articles by O’Donnell, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, P. T.
Right arrow Articles by O’Donnell, J. R.

Adverse Drug Effects

Thalidomide induced impotence in male hematology patients: a common but ignored complication?

Philip T. Murphy, John Rory O’Donnell

Department of Haematology, Beaumont Hospital, Dublin, Ireland

Correspondence: Philip T. Murphy, Department of Haematology, Beaumont Hospital, Dublin 9, Ireland. Phone: international +353.1.8092622; Fax: international +353.1.8093319. E-mail: philipmurphy{at}beaumont.ie

Thalidomide has become an important agent in the treatment of myeloma. However, thalidomide induced erectile dysfunction is a serious complication which has received very little attention. In our hematology department, 6 out of 11 male patients developed erectile dysfunction (grade 3 in 5/6) within 4 weeks of starting thalidomide. Our results suggest that thalidomide induced impotence is a common complication in male hematology patients.

Key words: myeloma, thalidomide, erectile dysfunction.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.